Lets say that NP-1 gets approved, azixa gets approved, and ceplene (god willing) gets approved...long shots all except azixa, but we can hope
annual sales (VERY CONSERVATIVELY)
NP-1 $200M (they think $1B so i take 20%) ceplene $100M (they think $200M so i take 50%) azixa $100M (mygn says $1B and we get ~10%)
by my crude math that is $400M in sales with expenditures of $75M last year (not gonna happen every year!!!!) we have earnings of $325M on like 50M shares already diluted and no need for further money...uhm??? earnings of like $7.50 a share with a PE of 10 gives us how much in the s/p????